BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Status:
Recruiting
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab
Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma,
Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell
Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea